H1, a New York City-based company that provides data on doctors and researchers the world over, announced Wednesday that it has acquired London-based Faculty Opinions to help life science companies, research organizations and others leverage insights of top scientists, including Nobel Laureates.
With the acquisition—for which financial details were not disclosed—H1 can now provide Faculty Opinion’s data that highlights emerging research to users at academic institutions and other research organizations. H1 follows a SaaS subscription model through which customers purchase licenses to access its products and can add services packages as needed.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
“The acquisition of Faculty Opinions will significantly enhance H1’s value to our expansive network,” said Ariel Katz, CEO of H1, in an email provided by a representative.
He said the addition of Faculty Opinions’ content will allow users to discover the newest and most promising research findings; develop cutting-edge ideas; and collaborate with opinion leaders to improve medicine, scientific research and patient care.
The addition of Faculty Opinions complements the data service that H1 currently provides.
Last year, the company rolled out a product called H1 Trial Landscape that pharmaceutical companies could use in choosing clinicians and sites for research trials. That includes data on physician ethnicity that can be accessed to help ensure research is inclusive and conducted by a diverse group of clinicians.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The Faculty Opinions acquisition expands H1’s reach and opportunity to impact healthcare by bringing this data under one umbrella, Katz said.
“As we look to make healthcare more affordable and accessible we have to make data on the experts driving it and innovating in medicine more accessible,” he said. “That’s what we will do together.”
And an executive at Faculty Opinions expect that H1 will be able to extend its reach.
“We believe strongly that H1 will meaningfully accelerate Faculty Opinions’ mission by increasing community engagement and making Faculty Opinions’ content visible across the markets they serve,” said Vitek Tracz, founder and chairman of Faculty Opinions, in a statement.
Other organizations also offer healthcare provider data, such as Definitive Healthcare and John Snow Labs.
But H1 touts its vast database, insights and network as uniquely built to drive advances in the life sciences and medicine. Seven of the top 10 pharmaceutical companies in the world and several leading academic medical centers, including Columbia University and the University of Pennsylvania, use H1, according to the company.
The acquisition follows a $100 million raise H1 completed in November. The company said then that it would be using the money to expand its network of clinicians and researchers, in addition to developing new features and hiring more staff.
Photo: Warchi, Getty Images
